As with most infectious respiratory diseases, the numbers of cases of pneumococcal infection peak during winter. Up to 50% of people can carry pneumococci in their nose and throat without developing serious infection.
Streptococcus pneumoniae (S. pneumoniae) is the bacterium responsible for causing pneumococcal infection and is characterised by its outer coat, known as capsular polysaccharide. Different capsular types can be distinguished via a process known as serotyping. There are about 90 different types of pneumococci, about a quarter of which cause serious illness.
For public information on pneumococcal disease, visit NHS Inform.
- For more information on pneumococcal immunisation, including updates, please refer to thePublic Health England (PHE) Green Book, Chapter 25.
- For information on the health protection management of pneumococcal disease clusters please visit the Public Health England website.
For all infection prevention and control guidance visit the A-Z pathogens section of the National Infection and Prevention Control Manual.
Data and surveillance
Invasive Pneumococcal Disease (IPD) surveillance is based on local and reference laboratory reports confirming isolation of S. pneumoniae from sterile body sites, mainly blood and CSF. In 1999, the Scottish Pneumococcal Invasive Disease Enhanced Reporting (SPIDER) scheme was introduced. The enhanced surveillance scheme is jointly managed by HPS and the Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory (SHLMPRL). Data from SPIDER informs understanding of the epidemiology of IPD in Scotland.
Surveillance update for April to June 2020
Thirty-nine cases of IPD were reported in the second quarter of 2020, bringing the total for the first two quarters to One hundred and forty-eight cases of IPD were reported in the first quarter of 2020. This is considerably lower than the number of cases reported for the corresponding period in the previous four years, which ranged from 340 to 410, as shown in Figure 1.
Figure 1: Cumulative number of IPD cases reported to SPIDER, 2016 to 2020 (to week 26)
Figure 2 includes data on cases reported in the first and second quarter of 2020 and indicates that IPD continues to occur more frequently in older age groups:
- 89 (47.3%) were 65 years or older
- 78 (41.5%) were 35 to 64 years old
- 9 (4.8%) were aged 15 to 34 years
- One (0.5%) was aged 5 to 14 years old
- 11 (5.9%) were under five years old, of whom three were aged under one year
Figure 2: Cases of IPD reported to SPIDER by quarter and by age group, 1999 to 2020 (to week 26)
IPD in children under five years old
Of the 188 IPD cases reported between January and June 2020, 11 were in children under five years of age and eligible for PCV13 vaccination. This is lower than the number of cases reported in this age group for the corresponding period in the previous four years, which ranged from 19 to 29. Serotypes detected in children aged under five years in the first quarter of 2020 are shown in Table 1.
|Serotype||Less than or equal to 2 months||3 to 11 months||1 year||2 years||3 years||4 years||Total under 5 years|
Enhanced surveillance questionnaires were returned for ten of the 11 cases aged under five years. Septicaemia was the most common clinical presentation. Other presentations were pneumonia pleural empyema and peritonitis.
Of the ten cases for whom enhanced surveillance questionnaires were returned:
- three (30.0%) were known to have an underlying risk factor
- eight (80.0%) are known to have been discharged alive
- one (10.0%) case was not yet discharged when the form was completed
- one (10.0%) case is known to have died
Circulating serotypes of Streptococcus pneumoniae
All IPD isolates and specimens should be sent to the reference laboratory for further typing and antimicrobial sensitivities. Typing results were available for 144 of the 188 (76.6%) cases reported in the first and second quarter of 2020.
The most common serotypes reported were:
- 8 (34 cases)
- 3 (17 cases)
- 9N (15 cases)
A total of 30 cases (16.0%) were caused by serotypes included in PCV13 vaccine, none of whom were aged under five years.
Two pneumococcal vaccines are available that help to protect against pneumococcal disease.
The pneumococcal polysaccharide vaccine, PPV23, is recommended for many of the same people who receive an annual flu vaccination. Unlike the flu vaccine which is given every year, the pneumococcal vaccine is usually only given once. In 2003, the pneumococcal vaccination for all people aged 65 years and over was introduced, in addition to those aged under 65, with certain underlying conditions. This vaccine offers protection against 23 serotypes of IPD.
In September 2006, the pneumococcal conjugate vaccine PCV7 was introduced into the routine childhood immunisation schedule. In spring 2010, PCV7 was replaced with PCV13 to provide broader protection against more serotypes of S. pneumoniae. PCV13 was initially offered as three doses; primary doses at eight and 16 weeks of age, followed by a booster at 12 to 13 months. From April 2020, the PCV13 schedule changed to a primary dose at 12 weeks followed by a booster dose at between 12 and 13 months. PCV13 offers protection against the following 13 serotypes of S. pneumoniae:
To coincide with the introduction of PCV7, enhanced surveillance was established for children under five years of age.
Vaccine uptake statistics
PCV13 uptake statistics are published by Public Health Scotland Data and Intelligence.